Fortis Healthcare share price today

Fortis Healthcare Ltd's share price was ₹790.65 at the close on 4 November 2026. It has been falling for 4 weeks. That is 10.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹713 and ₹1,020, and at that close it sat 25% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Fortis Healthcare Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 20 weeks running.

Over the last 11 years the share price moved +362% while the NIFTY 500 moved +249%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 25 June 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), indian funds and insurers (DIIs) raised their stake for 4 quarters in a row and foreign funds (FIIs) cut their stake for 4 quarters in a row.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹2,545 crore, +17.4% on a year earlier.

2. Indian funds and insurers (DIIs) raised their stake for 4 quarters in a row

   From 29.1% to 34.5% of the company by the September 2026 quarter.

3. Foreign funds (FIIs) cut their stake for 4 quarters in a row

   From 27.9% to 23.2% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Fortis Healthcare reported revenue of ₹2,545 crore, up 17.4% from ₹2,167 crore a year earlier, and a profit of ₹273 crore, up 2.2% from ₹267 crore.

Fortis Healthcare results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Fortis Healthcare's management discussed these results on a call held on 4 September 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Fortis Healthcare closed at ₹790.65 on 4 November 2026, down 22.5% from ₹1,020.00 a year earlier (7 November 2025) and up 213.3% over five years. Its highest weekly close since March 2016 was ₹1,084.90 on 17 October 2025.

Fortis Healthcare share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 4 March 2016 to 4 November 2026.

4 Nov 2026: Fortis Healthcare closed at ₹790.65, up 2.9% on the week and up 0.7% on the month. 4 Sep 2026: Fortis Healthcare held its results call for April to June 2026. Management guided: IHH to keep backing Fortis, provide capital if needed within legal limits and consider a Gleneagles-Fortis merger at the appropriate time; internal accruals to drive most growth.

Earlier

• 24 Jul 2026: ex-date for a dividend of ₹1 a share.
• Results for April to June 2026: Revenue up 17.4% and profit up 2.2% on a year earlier.

Fortis Healthcare paid ₹1 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.13% at the ₹790.65 close on 4 November 2026. The last was a dividend of ₹1 a share, ex-date 24 July 2026.

Fortis Healthcare dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Fortis Healthcare Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 4 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 4 September 2026, Fortis Healthcare's management guided: IHH to keep backing Fortis, provide capital if needed within legal limits and consider a Gleneagles-Fortis merger at the appropriate time; internal accruals to drive most growth.

“However, I am not sure why they are wrongly accusing us of wrongdoing when we are neither the judgment debtors nor were we garnishees at any stage. It is unfair to us, so we will definitely consider whatever actions we can take to protect the interests of our company.”Dr. Ashutosh Raghuvanshi, MD & CEO, on the call for April to June 2026

What management guided

• IHH commitment to raise its Fortis stake to 50% and above continues; timeframe not restated on this call.
• Fortis will cooperate if the audit proceeds; counsel to determine challenge or other steps over the next 5-10 days.
• Court-directed audit process: questionnaire in 4 weeks, responses in 2 weeks and report in 6 months; post-report actions may take a few months.
• Ongoing legal expenditure to continue; current-year level difficult to predict and dependent on case intensity.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 4 September 2026.

When Fortis Healthcare reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Court-directed audit to reach each stated procedural milestone, including information requests, responses and the final report.

Fortis Healthcare is on one of our India lists: Small & mid cap stocks.

Fortis Healthcare Ltd earned ₹273 Cr of net profit in the Jun 2026 quarter, +2.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹1,064 Cr. Over 10 years profit has grown 38.2% a year on average. That is 10.7% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹267 Cr.

For the full year, FY26 profit was ₹1,064 Cr (+31.5% on the year before).

Why profit moved: revenue changed +17.4% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +23.6% and revenue +17.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Fortis Healthcare Ltd reported ₹2,545 Cr of revenue in the Jun 2026 quarter, +17.4% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 10 years it has grown 8.1% a year on average. The last full year, FY26, came in at ₹9,128 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹9,506 Cr.

FY26 revenue was ₹9,128 Cr, +17.3% on the year before.

Recent pace: the last four quarters grew +17.5% on average, against 8.1% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +17.5%, against +15.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +18.6%, against +24.1% a year (rolling over).

Fortis Healthcare Ltd's operating margin was 21.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 2.0% and 23.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −1.5 percentage points on the year while gross margin changed +1.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 164% of Fortis Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,601 Cr of operating cash against ₹1,064 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹2,282 Cr of spending on assets, free cash was −₹681 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 164% of profit came in as cash: the cash cycle got 36 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 3.6× depreciation over three years. The next section checks what that spending is building.

Fortis Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −99 days in FY26, up from −135 days in FY21. It spent ₹4,187 Cr on assets over the last 3 years. Customers take 42 days to pay, and stock sits for 24 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹9,128 Cr, each day of that cycle ties up about ₹25.0 Cr, so roughly −₹2,476 Cr is tied up in the business at any time.

FY26: customers took 42 days to pay and stock sat for 24 days, about 0.8 months of sales sitting as stock, for a full cycle of −99 days, longer than FY21's −135.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 24 days. Customers pay about 42 days after that. Suppliers are paid at 165 days. Together that makes the −99-day cycle.

Spending on assets: ₹4,187 Cr over the last 3 years, against ₹1,177 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹434 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Fortis Healthcare Ltd's P/E is 56.0×, in the middle of its own history: higher than 40% of past readings. Its usual P/E (the middle reading) is 61.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹13.88.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.